SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
-12.98%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$280M
AUM Growth
+$280M
(-15%)
Cap. Flow
-$30M
Cap. Flow
% of AUM
-10.71%
Top 10 Holdings %
Top 10 Hldgs %
51.06%
Holding
103
New
34
Increased
13
Reduced
15
Closed
27
Top Buys
| 1 |
Amgen
AMGN
|
$21.5M |
| 2 |
Biogen
BIIB
|
$13.3M |
| 3 |
Boston Scientific
BSX
|
$12.9M |
| 4 |
Envista
NVST
|
$12.8M |
| 5 |
SPDR Gold Trust
GLD
|
$9.58M |
Top Sells
| 1 |
Medtronic
MDT
|
$16.7M |
| 2 |
Pfizer
PFE
|
$14.9M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$14.8M |
| 4 |
Gilead Sciences
GILD
|
$12.1M |
| 5 |
GSK
GSK
|
$9.62M |
Sector Composition
| 1 | Healthcare | 89.79% |
| 2 | Technology | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $21.5M | 7.21% | +106,069 | New | +$21.5M |
|
2
McKesson
MCK
$85.4B
| $17.9M | 6% | 132,340 +63,901 | +93% | +$8.64M |
|
3
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $17.5M | 5.86% | 1,077,839 +131,078 | +14% | +$2.13M |
|
|
GWPH
4
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $14.7M | 4.93% | 168,044 -17,713 | -10% | -$1.55M |
|
|
5
Biogen
BIIB
$19.4B
| $13.3M | 4.45% | +41,938 | New | +$13.3M |
|
6
Elevance Health
ELV
$71.8B
| $13.1M | 4.4% | 57,869 +27,130 | +88% | +$6.16M |
|
|
7
Boston Scientific
BSX
$156B
| $12.9M | 4.33% | +395,747 | New | +$12.9M |
|
|
8
Envista
NVST
$3.52B
| $12.8M | 4.29% | +856,922 | New | +$12.8M |
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $9.74M | 3.26% | 55,000 -41,931 | -43% | -$7.43M |
|
|
10
SPDR Gold Trust
GLD
$107B
| $9.58M | 3.21% | +64,702 | New | +$9.58M |
|
11
United Therapeutics
UTHR
$13.8B
| $8.61M | 2.89% | 90,823 -41,841 | -32% | -$3.97M |
|
|
BMY.RT
12
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $8.54M | 2.86% | +2,246,900 | New | +$8.54M |
|
13
Vanda Pharmaceuticals
VNDA
$279M
| $7.47M | 2.5% | +721,193 | New | +$7.47M |
|
14
Merck
MRK
$210B
| $7.16M | 2.4% | 93,083 -76,672 | -45% | -$5.9M |
|
15
HCA Healthcare
HCA
$94.5B
| $7M | 2.35% | 77,932 -31,667 | -29% | -$2.85M |
|
|
IMAB
16
I-MAB
IMAB
$340M
| $6.15M | 2.06% | +472,675 | New | +$6.15M |
|
17
UnitedHealth
UNH
$281B
| $5.46M | 1.83% | +21,900 | New | +$5.46M |
|
18
Teva Pharmaceuticals
TEVA
$21.1B
| $5.14M | 1.72% | +572,681 | New | +$5.14M |
|
|
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
| $5.04M | 1.69% | 387,402 +287,402 | +287% | +$3.74M |
|
20
Molina Healthcare
MOH
$9.8B
| $5.03M | 1.68% | 35,973 -37,263 | -51% | -$5.21M |
|
21
Zimmer Biomet
ZBH
$21B
| $4.75M | 1.59% | +47,000 | New | +$4.75M |
|
22
Quanterix
QTRX
$211M
| $4.36M | 1.46% | +237,081 | New | +$4.36M |
|
23
MEI Pharma
MEIP
$160M
| $4M | 1.34% | 2,485,098 +86,246 | +4% | +$139K |
|
|
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.58M | 1.2% | 85,153 -4,204 | -5% | -$177K |
|
25
Ardelyx
ARDX
$1.53B
| $3.53M | 1.18% | 621,534 | – | – |
|